Small molecules for big clinical needs

GizaVC invests in the vision of Israel's most innovative entrepreneurs.


Can-Fite, a developer of small molecule-based drugs, has an advanced pipeline of proprietary compounds in Phase II and Phase III clinical development addressing autoimmune-inflammatory and cancer diseases. Its lead drug candidate is in advanced clinical development for the treatment of rheumatoid arthritis and psoriasis. Can-Fite also holds 82 percent of US-traded OphthaliX Inc., which develops drugs for ophthalmic indications, including dry eye syndrome, glaucoma and uveitis.

canfite c



Prof. Pnina Fishman, Dr. Ilan Cohn 


CEO: Prof. Pnina Fishman         COO & CFO: Motti Farbstesin

VP Business Development: Sari Fishman



Fields of invesment: icon lifeHealthcare

Contact info: Website